COMPASS Pathways Helping People Overcome Depression, Makes History During September Wall Street Debut

Last month, COMPASS Pathways became the first psychedelic medicine company to go public on a major U.S. exchange. The company has patented a synthetic version of the active ingredient in so-called magic mushrooms for use in treatment-resistant depression. George Goldsmith, CEO of COMPASS Pathways, explains why the company chose to go public last month and how psilocybin is helping patients with treatment-resistant depression.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.